4475 EXECUTIVE DRIVE, SAN DIEGO, CA
Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
Announces $1.2 Million Registered Direct Offering
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
News, Articles of Incorporation
Calidi Biotherapeutics Enters New Lease Agreement Saving $1.1 Million Annually
Appoints Former Executive Corsee Sanders, Ph.D., to Board of Directors
Election of Scott Leftwich as Class III Director at Annual Meeting
News, Securities Holder Rights or Indentures
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload